Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026
Company Deals PIC

CellStore Signs Strategic Partnership Memorandum With Shanghai Cell Therapy Group – Deepening Cooperation in Cell Cryopreservation, Product Application Validation, and Industrial Synergy Across Cell and Gene Therapy

Fineline Cube Sep 10, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Deals

Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers

Fineline Cube Sep 10, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug

Jiangsu Hengrui Pharmaceuticals Advances HRS-5965 with NMPA Clinical Trial Approval for Glomerular Diseases

Fineline Cube May 9, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent pharmaceutical company based in China, has...

Company

Organon’s Q1 2024 Revenues Rise 7% YOY, Women’s Health and Biosimilars Lead the Way

Fineline Cube May 9, 2024

Organon (NYSE: OGN), a leading women’s health specialist, announced a 7% year-on-year increase in revenues...

Company Drug

Innovent Biologics’ Mazdutide Shows Superiority in Type 2 Diabetes Phase III Trial

Fineline Cube May 9, 2024

Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...

Company Medical Device

Blue Sail Medical’s New Catheter Receives NMPA Approval for Complex Coronary Lesion Treatment

Fineline Cube May 9, 2024

China’s Blue Sail Medical Co., Ltd (SHE: 002382) has received marketing approval from the National...

Company Drug

Abbisko and Allist Pharmaceuticals Initiate Phase II Trial for NSCLC Drug Combination

Fineline Cube May 9, 2024

Abbisko Therapeutics Co., Ltd (HKG: 2256) and Allist Pharmaceuticals Co., Ltd have announced the upcoming...

Company R&D

Profluent’s Neural Network Model Designs High-Efficiency CRISPR Gene-Editing System

Fineline Cube May 8, 2024

Biotechnology company Profluent has announced a significant advancement in the field of gene editing with...

Company Drug

Boehringer Ingelheim’s Anti-Sema3A BI 764524 Shows Promise in Diabetic Macular Ischemia Trial

Fineline Cube May 8, 2024

Boehringer Ingelheim (BI) has announced the publication of results from a Phase I/IIa clinical trial...

Company Drug

Pfizer Pauses Dosing in DMD Gene Therapy Trial Following Participant’s Sudden Death

Fineline Cube May 8, 2024

This week, Pfizer Inc. (NYSE: PFE) announced the unfortunate sudden death of a participant in...

Company Deals

Tonghua Dongbao Pharmaceuticals Inks Licensing Deal for Semaglutide in China

Fineline Cube May 8, 2024

Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has entered into a licensing agreement...

Company Drug

J&J’s Erleada Plus ADT Shows 0% Biochemical Recurrence Rate in High-Risk Prostate Cancer Trial

Fineline Cube May 8, 2024

Johnson & Johnson (J&J; NYSE: JNJ) has announced that its Phase II clinical trial for...

Company Deals

China’s Sciwind Biosciences Partners with HK inno.N for Ecnoglutide Rights in South Korea

Fineline Cube May 8, 2024

China’s Sciwind Biosciences Co., Ltd has entered into a licensing and partnership agreement with South...

Company

Siemens Healthineers Reports 3% YOY Growth in Q2 2024 Fiscal Report Amidst Challenging Comparison

Fineline Cube May 8, 2024

Germany’s medical technology leader Siemens Healthineers AG (ETR: SHL) has reported its financial results for...

Company

AstraZeneca Hong Kong Launches ‘HRDetect’ Program to Offer Free Genetic Testing for Cancer Patients

Fineline Cube May 8, 2024

AstraZeneca (AZ, NASDAQ: AZN) Hong Kong has announced a partnership with Inocras Hong Kong Ltd...

Company Deals

Siemens Healthineers AG Forges Expanded Partnership with Xi’an Daixing Hospital

Fineline Cube May 8, 2024

Germany’s Siemens Healthineers AG (ETR: SHL) has entered into an eight-year value partnership with Xi’an...

Company Drug

Everest Medicines’ Velsipity for UC Receives First Asian Approval in Macau

Fineline Cube May 8, 2024

Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that the regulatory authority in...

Company Drug

Wanbangde Pharmaceutical’s Huperzine A Earns FDA Rare Pediatric Disease Designation for HIE Treatment

Fineline Cube May 8, 2024

China’s Wanbangde New Building Materials Co., Ltd (SHE: 002082) has announced that its subsidiary, Wanbangde...

Company Medical Device

Andon Health’s Triplex Virus Test Kit Receives US FDA Emergency Use Authorization

Fineline Cube May 8, 2024

Andon Health Co., Ltd (SHE: 002432), a leading healthcare company based in China, has announced...

Company Deals

Citi Pharma Ltd and Hangzhou Newsea Technology Form JV to Boost API Production

Fineline Cube May 8, 2024

Pakistan-based pharmaceutical company Citi Pharma Ltd is entering into a joint venture (JV) agreement with...

Company Medical Device

Medtronic’s RDN System Symplicity Spyral Earns First-Ever NMPA Approval

Fineline Cube May 8, 2024

Medtronic (NYSE: MDT), the US-Irish medical device giant, has announced that its Symplicity Spyral renal...

Company Policy / Regulatory

Xi and Macron Discuss Enhanced Market Access for Foreign Investors, Focus on Life Sciences

Fineline Cube May 8, 2024

This week, talks between China’s President Xi Jinping and France’s President Emmanuel Macron in France...

Posts pagination

1 … 417 418 419 … 718

Recent updates

  • Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers
  • METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform
  • Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection
  • CSPC Wins NMPA Clinical Trial Approvals for Two Long‑Acting Injections – Weekly Rotigotine (SYH9087) for Parkinson’s Disease and World’s First Ready‑to‑Use Monthly Goserelin (SYH9102) for Solid Tumours
  • HBM Partner Solstice Oncology Launches with US$225 Million Series A Led by RA Capital – Advancing Second‑Generation CTLA‑4 Antibody Porustobart in Neoadjuvant Oncology
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers

Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Company Drug

CSPC Wins NMPA Clinical Trial Approvals for Two Long‑Acting Injections – Weekly Rotigotine (SYH9087) for Parkinson’s Disease and World’s First Ready‑to‑Use Monthly Goserelin (SYH9102) for Solid Tumours

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.